

SUPPORTING TECHNOLOGY READINESS OF NOVEL POC PLATFORM

21 April 2017

- **Anteo successfully completes Milestone 1 and progresses to next phase of its partnership study**
- **Initial studies demonstrate high detection sensitivity**

Anteo Diagnostics Limited (ASX: ADO) recently formed a partnership with Planet Innovation, Deakin University and DMTC to further the technology readiness of Planet Innovation's (Nplex) low cost, high sensitivity point of care diagnostic system using breakthrough reader technology.

Anteo's contribution and objectives in Milestone 1 were to successfully functionalise nanoparticles requiring integration with Planet Innovation's reader. Anteo has successfully established, optimised and verified a model lateral flow system for the nominated target assay using Mix&Go. Using the model lateral flow system, it has already matched and possibly exceeded sensitivity benchmarks developed by a US based assay development company. This benchmark has previously been reported to show equivalence to commercially available tests.

Anteo has started Milestone 2, which is focused on building further robustness and reproducibility of its conjugates while progressively driving for maximum achievable assay sensitivity. "Anteo expects to provide the partnership with a robust technical and commercial solution that can be applied to many different assays and not just the target assay currently being investigated," said Anteo Technologies Head of R&D Charlie Huang. Milestone 2 is scheduled to be completed by next quarter.

The DMTC Medical Countermeasures (MCM) program recognises the increasing important need to create an integrated multidisciplinary network focussed on MCM product development. Nplex Managing Director Dr Sacha Dopheide said, "First pass optimisation indicates that Anteo's conjugate and assay chemistry is performing above expectations with a respectable signal to noise ratio. We are encouraged by the results on Milestone 1 and look forward to seeing where Anteo can take their technology in this project."

Anteo has a vision to provide functional nanometre-thin coatings and binders across multiple industries and applications. In this area, we focus on improving the performance of PoC platforms through integration of our technologies with our partners cutting edge technologies and jointly achieve better clinical diagnostic outcomes for end customers.

The global market size for POC diagnostics alone is projected to reach \$36.96 billion USD by 2021*.

* *Markets & Markets*

ABOUT ANTEO GROUP – Anteo Diagnostics Limited (ADO:ASX) & Subsidiaries

Anteo Group is a global nanochemistry technology and medical supply group, developing, commercialising, manufacturing and distributing products for the life sciences, clinical diagnostics and bioseparations markets, and creating new applications in the energy and medical devices sectors.

Through Anteo Technology, the Anteo Group owns a patented nanochemistry surface engineering technology which unites the strength and stability of covalent binding with the gentleness of passive binding through multi-point chelation. Through the use of its reagents binders, coatings or primers, Anteo provides materials and services for high-value commercial applications. Markets include protein binding and antibody coupling (e.g. point of care devices), primers for in-vivo medical devices and medical drug delivery, and coatings with commercial applications across a broad range of industry sectors, including life sciences, in vitro diagnostics, medical devices and energy.

Through its wholly owned subsidiary, DIAsource Immunoassays SA, Anteo Group manufactures and distributes a complete catalogue of ELISA and RIA products for clinical diagnostics via established distribution channels in 75 countries across the world, including antibodies and laboratory automation instrumentation.

For more information, please visit www.anteodx.com